208 related articles for article (PubMed ID: 32184607)
21. An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate.
Kern Sliwa J; Savitz A; Nuamah I; Mathews M; Gopal S; Elefant E; Najarian D; Alphs L
Perspect Psychiatr Care; 2018 Oct; 54(4):530-538. PubMed ID: 29446084
[TBL] [Abstract][Full Text] [Related]
22. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
[TBL] [Abstract][Full Text] [Related]
23. Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia.
Fernández-Miranda JJ; Díaz-Fernández S; De Berardis D; López-Muñoz F
J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33915786
[TBL] [Abstract][Full Text] [Related]
24. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
[TBL] [Abstract][Full Text] [Related]
25. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
[TBL] [Abstract][Full Text] [Related]
26. Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review.
Edinoff AN; Doppalapudi PK; Orellana C; Ochoa C; Patti S; Ghaffar Y; Cornett EM; Kaye AJ; Viswanath O; Urits I; Kaye AM; Kaye AD
Front Psychiatry; 2021; 12():699748. PubMed ID: 34621193
[TBL] [Abstract][Full Text] [Related]
27. Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.
Samtani MN; Nandy P; Ravenstijn P; Remmerie B; Vermeulen A; Russu A; D'hoore P; Baum EZ; Savitz A; Gopal S; Hough D
Br J Clin Pharmacol; 2016 Nov; 82(5):1364-1370. PubMed ID: 27333588
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study.
Richarz U; Han J; Bai YM; Yu-Hai Chen E; Chung YC; Jhanwar VG; Kim SW; Sulaiman AH; Knight K; Gopal S
Medicine (Baltimore); 2023 Aug; 102(34):e34623. PubMed ID: 37653768
[TBL] [Abstract][Full Text] [Related]
29. One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients', Relatives', and Mental Health Professionals' Perspectives.
Spoelstra SK; Bruins J; Bais L; Seerden P; Castelein S; Knegtering H
Patient Prefer Adherence; 2022; 16():615-624. PubMed ID: 35283623
[TBL] [Abstract][Full Text] [Related]
30. Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting.
Cirnigliaro G; Battini V; Cafaro R; Mosini G; Vanzetto S; Prodi T; Macellaro M; Leuzzi R; Conti D; Carnovale C; Dell'Osso B
Expert Rev Neurother; 2023; 23(11):1031-1039. PubMed ID: 37750003
[TBL] [Abstract][Full Text] [Related]
31. Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia.
El Khoury AC; Patel C; Mavros P; Huang A; Wang L; Bashyal R
Neuropsychiatr Dis Treat; 2021; 17():3159-3170. PubMed ID: 34703236
[TBL] [Abstract][Full Text] [Related]
32. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.
Magnusson MO; Samtani MN; Plan EL; Jonsson EN; Rossenu S; Vermeulen A; Russu A
CNS Drugs; 2017 Apr; 31(4):273-288. PubMed ID: 28258365
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.
Zhao J; Li L; Shi J; Li Y; Xu X; Li K; Zhang L; Cai S; Feng Y; Zhuo J; Liu W; Lu H
Neuropsychiatr Dis Treat; 2017; 13():2045-2056. PubMed ID: 28814873
[TBL] [Abstract][Full Text] [Related]
34. Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis.
Li G; Keenan A; Daskiran M; Mathews M; Nuamah I; Orman C; Joshi K; Singh A; Godet A; Pungor K; Gopal S
Patient Prefer Adherence; 2021; 15():2239-2248. PubMed ID: 34629867
[TBL] [Abstract][Full Text] [Related]
35. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
Gutiérrez-Rojas L; Sánchez-Alonso S; García Dorado M; López Rengel PM
CNS Drugs; 2022 May; 36(5):517-527. PubMed ID: 35460508
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia.
Turkoz I; Wong J; Chee B; Siddiqui U; Knight RK; Richarz U; Correll CU
Ther Adv Psychopharmacol; 2023; 13():20451253231200258. PubMed ID: 37786804
[TBL] [Abstract][Full Text] [Related]
37. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.
Fu DJ; Turkoz I; Walling D; Lindenmayer JP; Schooler NR; Alphs L
Schizophr Res; 2018 Feb; 192():185-193. PubMed ID: 28454922
[TBL] [Abstract][Full Text] [Related]
38. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
Joshi K; Lafeuille MH; Brown B; Wynant W; Emond B; Lefebvre P; Tandon N
Curr Med Res Opin; 2017 Oct; 33(10):1763-1772. PubMed ID: 28741387
[TBL] [Abstract][Full Text] [Related]
39. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
Wallman P; Clark I; Taylor D
J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
[TBL] [Abstract][Full Text] [Related]
40. Cost-utility analysis of using paliperidone palmitate in schizophrenia in China.
Luo R; Lu H; Li H
Front Pharmacol; 2023; 14():1238028. PubMed ID: 37601057
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
